An observational study in Cardiogenic Shock, Acute Myocardial Infarction and STEMI - ST Elevation Myocardial Infarction, sponsored by Henry Ford Health System. Active, not recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Henry Ford Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.
Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 13th largest by enrollment of the 25 observational ones that give a count, is one of 7 that started in 2022, is one of 25 observational ones, reaches primary completion later than 1 of the 22 other live ones, and was the 33rd registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
Thomas Jefferson University · Sites in United States
Ages 18+
Atlantic Health System · Sites in United States
Ages 18–100
Abiomed Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 30 across the 25 interventional studies, 124 across the 25 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.
Henry Ford Health System has 2 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Cardiogenic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06253104Tufts Medical CenterChanges in Skeletal Muscle Thickness in Patients With Acute Heart Failure | 2026-12-31 |
| NCT07402018Thomas Jefferson UniversityIntra-aortic Balloon Counterpulsation (IABC) Compliance | 2026-12-31 |
| NCT07825363NIRSense Inc.Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 50 studies in Shock, Cardiogenic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.
The National Cardiogenic Shock Initiative (NCSI) was an initial step in helping to provide team based protocolized care in AMICS. Over the past 5 years, further evaluation and research has helped identify additional best practices that may contribute to further improving outcomes.
Vasopressors have been identified as being independently associated with worse outcomes and MCS escalation may lead to improvement. While sites participating in the NCSI were early adopters of MCS in AMICS, MCS escalation was open ended and dictated by variable local practice patterns. This contributed to the overall low rate of MCS escalation which occurred in NCSI.
Approximately 30-40% of patients with AMICS have concomitant right ventricular failure (RVF), which is associated with worse morality and may therefore benefit from consideration of early right ventricular mechanical circulatory support (RV-MCS) devices.
A total of 20 total sites will be accepted into the CERAMICS study with the goal of gathering data and outcomes of 120 patients treated at participating centers. The study is expected to collect data for approximately 2 years. Prior to joining the study, each site must have broad adoption of the NCSI treatment algorithm as the standard of care for AMICS among at least 80% of the interventional cardiologists who take STEMI call, as confirmed by the site principal investigator (PI).
It is critically important to track consecutive AMICS patients at each site to assess outcomes by identifying the total sample size treated and to help identify if there were particular biases regarding the use of MCS or escalation of MCS. We will also track survival to hospital discharge of those AMICS patients not treated with MCS via an exclusion form, as well as with patients treated with MCS including when care deviates from the study protocol.
All study data collection is occurring retrospectively at each time-point only using EMR, and there will be no contact between study personnel and patients. Patients will be discharged or deceased at the time of study entry. During participation in the study, study sites will regularly screen all acute MI patient records (STEMI and NSTEMI) for patients who presented with cardiogenic shock (AMICS) via a screening form.
Patients who present with an acute myocardial infarction (AMI) with cardiogenic shock (AMICS) prior to PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cardiogenic Shock present as defined by the presence of 2 OR MORE of the following criteria prior to PCI:
Exclusion Registry Exclusion Criteria:
AMICS patients who meet any of the following study exclusion criteria will have a limited set of data collected via a single-page Patient Exclusion Form completed and submitted within 45 days of hospital discharge, which includes the reason for exclusion, date of index PCI, and assessment of patient survival to hospital discharge:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hospital discharge survival/survival at 30 days
Hospital discharge survival/survival at 30 days
Time frame: Hospital discharge survival/survival at 30 days
All-cause mortality at 1 year
All-cause mortality at 1 year
Time frame: All-cause mortality at 1 year
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 53 months is above that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.